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During 2012–2015, we tested respiratory specimens from 
patients with severe respiratory illness (SRI), patients 
with influenza-like illness (ILI), and controls in South 
Africa by real-time PCR for Mycoplasma pneumoniae, 
followed by culture and molecular characterization of 
positive samples. M. pneumoniae prevalence was 1.6% 
among SRI patients, 0.7% among ILI patients, and 0.2% 
among controls (p<0.001). Age <5 years (adjusted odd 
ratio 7.1; 95% CI 1.7–28.7) and HIV infection (adjusted 
odds ratio 23.8; 95% CI 4.1–138.2) among M. pneu-
monia–positive persons were associated with severe 
disease. The detection rate attributable to illness was 
93.9% (95% CI 74.4%–98.5%) in SRI patients and 80.7% 
(95% CI 16.7%–95.6%) in ILI patients. The hospitaliza-
tion rate was 28 cases/100,000 population. We observed 
the macrolide-susceptible M. pneumoniae genotype in all 
cases and found P1 types 1, 2, and a type 2 variant with 
multilocus variable number tandem repeat types 3/6/6/2, 
3/5/6/2, and 4/5/7/2.
In 1986, ≈4 million deaths were attributed to pneumonia in children <5 years old globally (1). This number declined 
to 1.2 million by 2011, largely because of interventions such 
as antimicrobial drugs and vaccination against leading pneu-
monia-causing pathogens (1). Despite this decline, pneu-
monia remains a major cause of illness and death globally, 
especially in children <5 years old (2).
Mycoplasma pneumoniae causes respiratory illness 
and pneumonia with estimated prevalence ranging 2%–
35%, depending on the identification method, the study 
period, and the population under investigation (3–5). Data 
from 21 countries showed M. pneumoniae to be the most 
common atypical pneumonia-causing bacterium, respon-
sible for ≈12% of community-acquired pneumonia during 
1996–2004 (6). M. pneumoniae epidemics have been re-
ported to occur in cycles of 3–5 years (5,7). Persons in-
fected with M. pneumoniae are treated with macrolides or 
azalide antibiotics (8); however, because of excessive and 
inappropriate use of antibiotics, macrolide resistance is in-
creasing (9–11).
Characterization of strains is important for outbreak 
investigations to understand disease epidemiology and 
to identify type switching that might occur because of 
population immune pressure. M. pneumoniae is typi-
cally characterized by typing the P1 adhesion molecule 
gene sequence, which distinguishes the 2 P1 types (12), 
or by using multilocus variable-number tandem-repeat 
analysis (MLVA), which is more discriminatory than 
P1 typing (13).
The prevalence of M. pneumoniae in South Africa is 
unknown because of the low availability of reliable tests 
and because clinicians rarely request testing. Here we de-
scribe the prevalence, epidemiology, molecular character-
istics, and antimicrobial resistance properties of M. pneu-
moniae among patients with mild and severe respiratory 
illness in South Africa.
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Materials and Methods
Study Design
We enrolled patients and asymptomatic persons during 
June 2012–May 2015 as part of 2 surveillance programs 
(1 for severe respiratory illness [SRI] and 1 for influen-
za-like illness [ILI]). SRI surveillance was conducted 
at 2 sentinel sites, Edendale Hospital in KwaZulu Natal 
Province and Klerksdorp-Tshepong Hospital Complex 
in North West Province. Patients enrolled in SRI sur-
veillance were those hospitalized with clinical signs and 
symptoms of lower respiratory tract infection (LRTI), 
regardless of symptom duration. We included children 2 
days to <3 months old who had physician-diagnosed sep-
sis or acute LRTI, children 3 months to <5 years old with 
physician-diagnosed LRTI, and persons >5 years old who 
met the World Health Organization case definition for 
LRTI (sudden onset of fever [temperature >38°C] or re-
ported fever, cough or sore throat, and shortness of breath 
or difficulty breathing [14]).
ILI patients were outpatients who were seen at 2 pri-
mary health care clinics serving the 2 SRI sentinel sites. 
Patients were considered to have ILI if they had an acute 
fever of >38°C or a self-reported fever within the last 7 
days and either a cough or sore throat. Asymptomatic 
persons included those who were seen at the same pri-
mary health care clinics and had no history of respira-
tory illness, diarrheal illness, or fever in the preceding 
14 days. For asymptomatic persons, we aimed to enroll 
1 HIV-infected and 1 HIV-uninfected person weekly in 
each clinic within the following age categories: 0–1, 2–4, 
5–14, 15–54, and >55 years.
We obtained demographic and clinical information 
from all enrollees by using a standardized questionnaire. 
We reviewed hospital records of SRI patients to assess dis-
ease progression and outcome.
Specimen Collection
We collected combined nasopharyngeal and oropharyn-
geal swabs from >5 year-old persons and nasopharyngeal 
aspirates from <5 year-old persons (nasopharyngeal speci-
mens) and placed the specimens in universal transport me-
dium (Copan Italia, Brescia, Italy). We collected induced 
or expectorated sputum from SRI patients only. HIV sta-
tus was determined as part of standard care or by using 
anonymized-linked dried blood spot testing for consenting 
enrollees (PCR for children <18 months old and ELISA 
for persons >18 months old [15]). We tested nasopharyn-
geal specimens for 10 respiratory viruses (influenza types 
A and B, adenovirus, enterovirus, rhinovirus, human meta-
pneumovirus, respiratory syncytial virus, and parainfluenza 
virus types 1–3) by using an in-house multiplex real-time 
reverse transcription PCR (16).
Detection of M. pneumoniae
We extracted DNA from 200 µL of nasopharyngeal speci-
men and digested sputum by using the MagNA Pure 96 
instrument (Roche Diagnostics, Mannheim, Germany) 
with the DNA and Viral NA SV kit (Roche Diagnostics). 
We performed an in-house multiplex real-time PCR for the 
detection of M. pneumoniae, Chlamydia (Chlamydophila) 
pneumoniae, and Legionella spp., with human ribonucle-
ase P gene serving as an internal control, as previously 
described (17). A positive M. pneumoniae patient was de-
fined as a patient having a positive PCR result with a cycle 
threshold value <45 for M. pneumoniae on the nasopharyn-
geal specimen, sputum specimen, or both.
Culture and Molecular Characterization
We detected 82 cases of PCR-positive M. pneumoniae dur-
ing study periods 1 (June 2012–May 2013) and 2 (June 
2013–May 2014) and performed culture and molecular 
characterization retrospectively on 77 (94%) samples. Cul-
ture and further characterization could not be performed for 
5 cases because of insufficient specimens.
We inoculated M. pneumoniae–positive specimens in 
SP4 medium (Thermo Fisher Scientific, Waltham, Massa-
chusetts, USA) and incubated them at 37°C in 5% CO2 for 
up to 10 days. Growth was indicated by a color change from 
red to orange, without turbidity. We performed macrolide 
susceptibility analysis by using real-time PCR followed 
by high-resolution melt-curve (HRM) analysis by means 
of the Rotor-Gene Q6000 system (QIAGEN, Hilden, Ger-
many), according to previously described methods (18).
We performed P1 genotyping by using real-time PCR 
targeting the 1900-bp region of the P1 gene, followed by 
HRM analysis using the Rotor-Gene Q6000 system ac-
cording to previously described methods (12). We also 
performed MLVA typing on the same specimens by us-
ing 5 variable-number tandem-repeat loci (Mpn1, Mpn13, 
Mpn14, Mpn15, and Mpn16), as described by Dégrange 
et al. (13). However, for analysis, we used the 4-loci no-
menclature as described by Sun et al. (19) because of the 
instability of the Mpn1 locus (20).
Statistical Analysis
We used the χ2 or Fisher exact test for comparison of 
categorical variables. We used unconditional logistic re-
gression to estimate the attributable fraction (AF) of M. 
pneumoniae–associated hospitalization and outpatient con-
sultation by comparing the M. pneumoniae detection rate 
among SRI or ILI patients to that of controls. The AF was 
estimated from the odds ratio (OR) obtained from the re-
gression models.
Among SRI patients, we estimated the AF for patients 
positive on nasopharyngeal specimens only as well as 
for patients positive on both nasopharyngeal and sputum 
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specimens. We adjusted all estimates for age, HIV status, 
underlying medical conditions other than HIV infection, 
and co-infections with the 10 respiratory viruses investi-
gated in this study.
In addition, we used unconditional logistic regression 
to assess factors associated with M. pneumoniae–associ-
ated SRI hospitalization by comparing the characteristics 
of M. pneumoniae–positive SRI patients with those of M. 
pneumoniae–positive ILI patients. For the multivariable 
model, we assessed all variables that were significant at 
p<0.2 on univariate analysis and dropped nonsignificant 
factors (p>0.05) with manual backward elimination. We 
assessed pairwise interactions by inclusion of product 
terms for all variables remaining in the final multivariable 
additive model. We performed the analysis by using Stata 
14 (StataCorp LLC, College Station, Texas, USA). Season-
ality and periodicity were assessed over 3 periods (period 
1, June 2012–May 2013; period 2, June 2013–May 2014; 
and period 3, June 2014–May 2015).
Calculation of Rates of M. pneumoniae–Associated 
SRI Hospitalization
We estimated the overall and age-specific rates of M. 
pneumoniae–associated SRI hospitalizations (per 100,000 
population) by using the number of SRI hospitalizations 
and adjusting for nonenrollment (e.g., refusals to partici-
pate and no enrollment on weekends [21]) and healthcare-
seeking behavior during 2013–2014. For all calculations, 
we assumed that the M. pneumoniae detection rate among 
persons tested and not tested was the same within age 
groups. We obtained age- and year-specific population de-
nominators from projections of the 2011 census data (21), 
and we obtained age- and year-specific HIV prevalence in 
the study population from the projections of the Thembisa 
model (22).
We calculated 95% CIs for all estimated rates by 
using bootstrap resampling of all parameters included in 
the estimation over 1,000 replications. The upper and 
lower limits of the 95% CI were the 2.5th and 97.5th 




During June 2012–May 2015, we enrolled 11,391 per-
sons, of whom 10,194 (89.5%) had specimens collected 
that were tested for M. pneumoniae. Of these specimens, 
4,703 (46.1%) were from SRI patients, 3,721 (36.5%) were 
from ILI patients, and 1,770 (17.4%) were from controls. 
Among the SRI patients, 2,390 (50.8%) had a nasopharyn-
geal specimen tested only, 207 (4.4%) had sputum tested 
only, and 2,106 (46.8%) had both specimen types tested.
Among persons for whom age was known, children 
<5 years old accounted for 35.8% (1,678/4,687) of SRI 
patients, 30.7% (1,142/3,716) of ILI patients, and 35.2% 
(662/2,767) of controls. HIV status was known for 86.5% 
(8,815/10,194) of enrollees. HIV prevalence was 54.2% 
(2,117/3,902) among SRI patients, 28.8% (940/3,261) 
among ILI patients, and 42.7% (705/1,652) among con-
trols (owing to enrollment criteria of controls) (p<0.001). 
Among SRI and ILI patients, HIV prevalence was lowest 
among infants <1 year old (SRI patients, 12.3% [99/805]; 
ILI patients, 2.5% [9/360]) and highest among persons 
25–44 years old (SRI patients, 90.6% [1,180/1,303]; ILI 
patients, 59.0% [588/997]).
Detection Rate of M. pneumoniae
Overall, we detected M. pneumoniae in 1.0% (103/10,194) 
of persons tested; this rate was 1.6% (73/4,703) among SRI 
patients, 0.7% (27/3,721) among ILI patients, and 0.2% 
(3/1,770) among controls (p<0.001). We also compared 
detection rates by age and HIV status (Table 1). Among 
patients with SRI, the detection rate of M. pneumoniae dif-
fered by specimen type (1.1% [49/4,496] in nasopharyn-
geal specimens vs. 1.7% [39/2,313] in sputum; p = 0.04). 
Among the 2,106 SRI patients with M. pneumoniae results 
available for both specimen types, 15 (0.7%) patients tested 
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Table 1. Mycoplasma pneumoniae detection rate, by age and HIV status, among inpatients with SRI, outpatients with ILI, and controls, 
Klerksdorp and Pietermaritzburg, South Africa, June 2012–May 2015* 
Characteristic 
No. positive/no. tested (%) 
SRI ILI Controls 
Total 73/4,703 (1.6) 27/3,721 (0.7) 3/1,770 (0.2) 
Age group, y    
 <1 19/1,067 (1.8) 3/397 (0.8) 0/249 (0.0) 
 1–4 19/611 (3.1) 8/745 (1.1) 0/373 (0.0) 
 5–24 9/383 (2.3) 8/1,085 (0.7) 3/505 (0.6) 
 25–44 16/1,492 (1.1) 6/1,075 (0.6) 0/271 (0.0) 
 45–64 7/885 (0.8) 1/360 (0.3) 0/258 (0.0) 
 >65 3/249 (1.2) 1/54 (1.9) 0/111 (0.0) 
HIV status    
 Negative 30/1,785 (1.7) 21/2,231 (0.9) 2/947 (0.2) 
 Positive 32/2,117 (1.5) 2/940 (0.2) 0/705 (0.0) 
*ILI, influenza-like illness; SRI, severe respiratory illness.    
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positive on both specimens, 10 (0.5%) tested positive on 
nasopharyngeal specimen only, 20 (0.9%) tested positive 
on sputum only, and 2,061 (97.9%) tested negative on both 
specimen types. Of M. pneumoniae–positive patients with 
known outcome, 98% (97/99) survived and 2% (2/99) died. 
Both patients that died were adults admitted for SRI and 
were receiving treatment for tuberculosis with no other re-
spiratory virus identified. One of these patients was HIV-
positive, and HIV status for the other patient was unknown.
We observed no seasonality (Figure). However, we 
detected a significantly higher rate of M. pneumoniae in 
periods 1 and 2 compared with period 3 (period 1, 1.4% 
[50/3,651] vs. period 2, 1.2% [35/2,846] vs. period 3, 0.5% 
[18/3,594]; p<0.001).
Overall, we detected M. pneumoniae along with an-
other virus or other atypical pneumonia-causing bacteria in 
65% (62/103) of patients. M. pneumoniae was co-detected 
with rhinovirus most frequently (58% [36/62]), followed 
by adenovirus (43% [27/62]), respiratory syncytial virus 
(18% [11/62]), influenza virus (13% [8/62]), human meta-
pneumovirus (8% [5/62]), enterovirus (6% [4/62]), parain-
fluenza virus (5% [3/62]), and C. pneumoniae (3% [2/62]).
AF of M. pneumoniae–Associated Hospitalization  
and Outpatient Consultation
The AF of M. pneumoniae detection to illness using na-
sopharyngeal specimens only for patients with ILI was 
80.7% (95% CI 16.7%–95.6%) and for patients with SRI 
was 90.1% (95% CI 58.3%–97.7%). The AF of M. pneu-
moniae detection to illness for patients with SRI using both 
nasopharyngeal and sputum specimens was 93.9% (95% 
CI 74.4%–98.5%).
Factors Associated with Hospitalization among  
M. pneumoniae PCR-Positive Patients
On multivariable analysis, we compared M. pneumoni-
ae–positive SRI patients to M. pneumoniae–positive ILI 
patients. Factors associated with increased risk of M. pneu-
moniae–associated hospitalization were age <5 years com-
pared with >5 years (adjusted odds ratio [aOR] 7.1; 95% CI 
1.7–28.7); HIV infection (aOR 23.8; 95% CI 4.1–138.2); 
and duration of symptoms >4 days (aOR 3.8; 95% CI 1.1–
14.4) (Table 2).
Rates of M. pneumoniae SRI Hospitalization
The mean annual rate of hospitalization for M. pneumoniae 
patients during 2013–2014 was 27.9 cases/100,000 popula-
tion (95% CI 18.9–37.4) (Table 3). HIV-infected persons had 
19.5 (95% CI 14.4–26.4) times greater odds of M. pneumoni-
ae–associated SRI hospitalization (102.2/100,000 [95% CI 
64.9–136.4) than did HIV-uninfected persons (14.9/100,000 
[95% CI 10.3–19.0]). The highest rate was in patients <5 
years old (220.0/100,000 [95% CI 121.0–314.8]).
Culture and Molecular Characterization
We obtained cultures for 11/77 (14%) M. pneumoniae–
positive specimens. HRM macrolide susceptibility profiles 
were available for 43% (33/77) of M. pneumoniae–positive 
specimens, and all were macrolide-susceptible.
We obtained HRM analysis results for P1 genotyping 
for 36% (28/77) of M. pneumoniae PCR-positive specimens 
(12). M. pneumoniae were P1 type 1 (29% [8/28]), P1 type 
2 (61% [17/28]), and a variant of P1 type 2 (11% [3/28]).
MLVA types were available for 51% (39/77) of PCR-
positive samples. On the basis of a combination of tandem 
repeats at the 4 loci, 3 distinct types were present: 3/5/6/2 
(17/39 [44%]), 3/6/6/2 (15/39 [38%]), and 4/5/7/2 (7/39 
[18%]). The remaining 49% (38/77) could not be assessed 
because of the inability to determine the fragment size of 
>1 of the 4 variable-number tandem-repeat loci.
Discussion
Overall, M. pneumoniae was detected in 1% of all patients 
(1.6% of SRI patients and 0.7% of ILI patients). Among 
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Figure. Number of 
Mycoplasma pneumoniae–
positive cases and detection 
rate among inpatients with 
SRI and outpatients with 
ILI (N = 8,424), by month 
and period, Klerksdorp and 
Pietermaritzburg, South Africa, 
June 2012–May 2015. ILI, 
influenza-like illness; SRI, 
severe respiratory illness.
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M. pneumoniae patients, young age (<5 years) and HIV in-
fection were associated with severe disease. M. pneumoni-
ae strains were susceptible to macrolides and represented 
3 P1 types. The higher detection rate of M. pneumoniae 
in periods 1 and 2 of the study suggests that there might 
be periodicity in M. pneumoniae infection in South Africa.
The prevalence of M. pneumoniae varies depending 
on whether a study was performed during an endemic or 
epidemic year, the laboratory detection method used, or 
the study participants (3). During 2010–2012, an epidemic 
of M. pneumoniae occurred in Denmark, England, Wales, 
Sweden, Finland, and Germany, with detection rates 
ranging from 12% to 17% (23–26). In France, detection 
rates of M. pneumoniae ranged from 2% to 10% during a 
5-year period among outpatients with an acute respiratory 
illness (5). However, higher detection rates of 27%–30% 
among children with community-acquired pneumonia 
have been reported in the United States and Finland and 
up to 60% among hospitalized adults with pneumonia in 
Japan (3,4,27). Jain et al. reported that, among hospital-
ized children in the United States, M. pneumoniae was 
the most common bacterial cause of community-acquired 
pneumonia, accounting for 8% of cases (28), and among 
hospitalized adults in the United States, M. pneumoniae 
was identified in ≈2% of cases (29). The prevalence dif-
ferences in our study compared with other studies might 
be attributable to a difference in enrollment criteria, the 
age group of participants, and HIV prevalence among 
the participants.
Despite having low detection rates, M. pneumoniae 
was significantly associated with illness. The fraction of 
illness attributable to M. pneumoniae in patients testing 
positive was 80.7% in ILI patients, 90.1% in SRI patients 
with M. pneumoniae detected on nasopharyngeal speci-
mens only, and 93.9% in SRI patients with M. pneumoniae 
detected on both nasopharyngeal and sputum specimens. 
These results suggest that M. pneumoniae can be consid-
ered a likely pathogen when detected in patients with ILI or 
SRI, regardless of specimen type.
We did not observe a distinct seasonal pattern of M. 
pneumoniae. Several more years of surveillance of M. 
pneumoniae is essential to elucidate seasonality in our set-
ting. However, a significant difference was noted in the de-
tection rate over the 3 study periods. Layani-Milon et al. 
reported that, during a 5-year period (1993–1997), rates of 
M. pneumoniae disease varied monthly and yearly and M. 
pneumoniae occurred in epidemic cycles (5). Furthermore, 
in a serologic study in Johannesburg, South Africa, during 
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Table 2. Factors associated with patients being hospitalized for ILI and SRI associated with Mycoplasma pneumoniae infection, 
Klerksdorp and Pietermaritzburg, South Africa, June 2012–May 2015* 




OR (95% CI) p value aOR (95%CI) p value 
Age <5 y 11/27 (40.7) 38/73 (52.1) 1.6 (0.6–3.9) 0.317  7.1 (1.7–28.7) 0.006 
Female sex 16/17 (59.3) 38/72 (52.8) 0.8 (0.3–1.9) 0.565    
Crowding, no. persons/room        
 <2 18/27 (66.7) 49/72 (68.1) Reference NA    
 3–4 7/27 (25.4) 19/72 (26.4) 1.0 (0.4–2.7) 0.996    
 >5 2/27 (7.4) 4/72 (5.6) 0.7 (0.1–4.4) 0.734    
Duration of symptoms >4 d 7/26 (26.9) 37/69 (53.6) 3.1 (1.2–8.4) 0.023  3.8 (1.1–14.1) 0.046 
HIV infection 2/23 (8.7) 32/62 (51.6) 11.2 (2.4–51.9) 0.002  23.8 (4.1–138.2) <0.001 
Any underlying medical condition‡ 3/27 (11.1) 10/72 (13.9) 1.3 (0.3–5.1) 0.716    
Any viral co-infection§ 13/27 (48.1) 47/73 (64.4) 1.9 (0.8–4.7) 0.144    
*Bold indicates statistical significance. aOR, adjusted OR; ILI, influenza-like illness; NA, not applicable; OR, odds ratio; SRI, severe respiratory illness. 
†Only variables found to be statistically significant (p<0.2) in univariate analysis were assessed in the multivariable model. 
‡Underlying conditions defined as previously diagnosed chronic conditions including asthma, chronic lung diseases, cirrhosis or liver failure, chronic renal 
failure, heart failure, valvular heart disease, coronary heart disease, diabetes, burns, kwashiorkor or marasmus, nephrotic syndrome, spinal cord injury, 
seizure disorder, emphysema, and cancer, or history of immunosuppressive therapy or splenectomy. 
§Viruses tested were influenza types A and B, adenovirus, enterovirus, rhinovirus, human metapneumovirus, respiratory syncytial virus, and 
parainfluenza virus types 1–3. 
 
 
Table 3. Incidence of hospitalization for Mycoplasma pneumoniae, by age group and HIV status, Klerksdorp and Pietermaritzburg, 
South Africa, January 2013–December 2014* 
Age group, y 
No. cases/100,000 population (95% CI) Risk ratio (95% CI), HIV 
infected vs. uninfected All patients HIV-infected patients HIV-uninfected patients 
<1 220.0 (121.0–314.8) 594.8 (316.4–873.2) 216.7 (128.3–303.8) 2.8 (0.4–18.6) 
1–4 53.9 (30.1–75.6) 961.7 (518.4–1391.6) 35.9 (21.1–50.2) 26.8 (14.4–49.8) 
5–24 14.1 (9.4–18.6) 130.0 (81.1–173.8) 5.5 (3.9–7.1) 23.8 (13.4–42.4) 
25–44 21.4 (15.0–27.6) 70.1 (46.3–95.1) 0 (0–46.7) NA 
45–64 26.2 (17.6–34.9) 118.7 (81.2–159.3) 4.7 (3.4–6.2) 25.6 (9.9–65.9) 
>65 56.2 (37.5–74.2) 0 (0–234.1) 57.8 (41.3–74.9) NA 
<5 87.1 (60.2–114.0) 927.3 (621.3–1231.5) 72.3 (50.5–93.8) 16.1 (9.4–27.6)† 
>5 20.5 (14.0–26.9) 91.3 (59.0–122.4) 6.3 (4.5–8.4) 21.6 (14.8–31.7)† 
All 27.9 (18.9–37.4) 102.2 (64.9–136.4) 14.9 (10.3–19.0) 19.5 (14.4–26.4)† 
*NA, not applicable. 
†Adjusted for age. 
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1969–1975, the periodicity of M. pneumoniae was shown 
to peak in 3-year intervals (7). During period 1 of our 
study, a cyclical epidemic of M. pneumoniae was probably 
occurring, and this epidemic reached its nadir in period 3 
of the study. Longer study periods are required to evaluate 
the cyclical nature of M. pneumoniae.
In our study, a large proportion (65%) of M. pneu-
moniae patients were co-infected with a respiratory virus, 
of which rhinovirus and adenovirus were the most com-
mon. Similarly, Lieberman et al. reported that, in 65% of 
M. pneumoniae patients, >1 additional pathogens were 
detected, of which Streptococcus pneumoniae (43%) and 
Legionella spp. (15%) were most frequently detected (30).
We found that young age (<5 years) and HIV infection 
among M. pneumoniae–positive persons were indepen-
dently associated with severe disease. HIV association with 
M. pneumoniae disease was reported in a study conducted 
in India during 2004–2007 (31). The incidence rate of M. 
pneumoniae in South Africa was 28 cases/100,000 popula-
tion, with the highest incidence occurring in children <5 
years old at a rate of 87 cases/100,000 population. We ob-
served a greater disease prevalence among HIV-infected 
patients than HIV-uninfected patients. Other studies have 
reported incidence rates ranging from 180 to 1,290 cas-
es/100,000 population/year (3,5,32). Studies have shown 
variability in detection rates among different age groups, 
especially in M. pneumoniae–endemic areas, where M. 
pneumoniae has occurred predominantly among children 
<5 years old (33,34).
A lack of consensus exists regarding the preferred 
specimen type for the identification of M. pneumoniae 
(35,36). We observed a significantly higher detection rate 
of M. pneumoniae in sputum compared to nasopharyngeal 
specimens, similar to results reported by Dorigo-Zetsma et 
al. (37) and Räty et al. (38). Although we detected a higher 
rate in sputum, nasopharyngeal specimens remain the pre-
ferred specimen type for surveillance because collecting 
a nasopharyngeal specimen is less invasive. In addition, a 
positive result on a nasopharyngeal specimen is a good in-
dicator of disease as indicated by the AF.
During the M. pneumoniae epidemic that occurred 
in Europe during 2010–2012, P1 type 1 was dominant 
(24,39). In our population, P1 types 1 and 2 were circu-
lating at equal frequencies. Likewise, in the United States, 
during an 8-year period (2006–2013) both P1 types were 
co-circulating (40). In China, during 2009–2011, P1 type 
1, type 2, and variants of type 2 were identified; however, 
a higher frequency of type 1 compared with the other P1 
types was observed (41). Continued surveillance is impor-
tant to identify longer-term trends in M. pneumoniae strain 
prevalence in South Africa.
By using the 4-loci MLVA typing scheme and no-
menclature, we identified 3 distinct MLVA types (3/6/6/2, 
3/5/6/2, and 4/5/7/2), which are the same types circulating 
in the United States, Kenya, Guatemala, Egypt, Denmark, 
and Canada (19,20,40,42). However, the predominance of 
MLVA type 3/5/6/2 in our study was different to what has 
been previously described elsewhere in the world. The pre-
dominant MLVA type circulating in numerous countries 
during 1962–2013 was MLVA type 4/5/7/2 (13,20,40). Al-
though no correlations of strain type with disease severity 
or outcomes have been established, these typing methods 
are useful for monitoring trends over time and during out-
break investigations.
Macrolide resistance of 17% was documented in M. 
pneumoniae in Japan during 2000–2003 (43), with even 
higher rates of up to 90% reported in China (44). In Ger-
many, 1.2% and 3% of M. pneumoniae found in respira-
tory tract specimens were resistant to macrolides during 
2003–2008 and 1991–2009, respectively (45). In a US 
study, macrolide resistance was reported for ≈3% of M. 
pneumoniae cases in patients hospitalized with communi-
ty-acquired pneumonia (46). However, other studies have 
reported macrolide resistance of 10%–13% in sporadic and 
outbreak specimens in the United States (40,47). Resis-
tance in Europe and the United States remains low relative 
to Asia, possibly because of the restricted availability of an-
timicrobial drugs. We did not identify macrolide resistance 
among the isolates in our study, and therefore macrolide 
treatment is probably effective against M. pneumoniae in 
our setting. However, excessive use of macrolides should 
be discouraged, given that in Japan inappropriate use of 
macrolides was shown to increase the likelihood of the or-
ganism developing mutations in the 23S rRNA gene (11). 
Therefore, identification of the etiologic cause of infection 
and its appropriate treatment are essential. In South Africa, 
first-line treatment for community-acquired pneumonia is 
penicillin (48). In severely ill persons or those in whom 
atypical pneumonia is suspected, macrolides are adminis-
tered. A limitation of our study is that treatment data for 
patients with M. pneumoniae were limited.
We performed molecular characterization for samples 
collected during periods 1 and 2 of our study. Most of the 
positive specimens were obtained during these 2 periods, 
and results from these periods can be inferred for period 3 
because no intervention was implemented. We obtained a 
low yield of isolates and were unable to determine the mac-
rolide susceptibility trait and strain type for a proportion 
of specimens, most likely because of a low bacterial load 
in the specimen, which might have affected the ability to 
detect resistance particularly if a low prevalence of macro-
lide-resistant M. pneumoniae strains exists in South Africa.
We have shown that, although the M. pneumoniae de-
tection rate was low, M. pneumoniae detection is probably 
associated with illness, underscoring the need for testing, 
especially among patients at higher risk for severe disease. 
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Such testing would result in an earlier diagnosis and im-
proved management. Our study provides baseline data that 
can be used for future surveillance programs to better un-
derstand M. pneumoniae epidemiology in South Africa.
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